Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02000089 · ClinicalTrials.gov registry record · Phase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
A Phase 3 study of Pancreas Cancer and Lynch Syndrome, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 9,000
- Enrollment target
- 9
- Study locations
NCT02000089: Recruiting Phase 3 study of Pancreas Cancer and Lynch Syndrome, sponsored by Johns Hopkins University.
NCT02000089 is a Phase 3 study of Pancreas Cancer and Lynch Syndrome that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 9,000 participants, above the 741-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (1115% higher). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02000089, a Phase 3 study of Pancreas Cancer and Lynch Syndrome, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 9,000 participants
- Enrollment target
- 9
- Study locations
Study Summary
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Primary Outcome
Aim #1: To evaluate pancreatic fluid mutations and circulating pancreatic epithelial cells as accurate markers of neoplasia by comparing their prevalence in cases with sporadic pancreatic neoplasia to healthy and disease controls.
Conditions Studied
Interventions
- DRUG Secretin
- DIAGNOSTIC_TEST MRI
- OTHER Tumor marker gene test with CA19-9
Study Locations (9)
New York
- NYU Langone Medical Center - New York
- Columbia University Medical Center - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburgh - Pittsburgh
Connecticut
- Yale University - New Haven
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Dana Farber Cancer Center, Harvard University - Boston
Michigan
- University of Michigan - Ann Arbor
Ohio
- Case Comprehensive Cancer Center, Case Western Medical Reserve - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,000 participants |
| Start Date | 2014-01-06 |
| Est. Completion | 2029-06 |
| Phase | Phase 3 |
What NCT02000089 shows while recruiting
NCT02000089 is an interventional study that assigns participants to a tested intervention. Its 9,000 participants enrollment target places it among the larger protocols in the corpus, above the 741-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (1115% higher).
The record links to 5 conditions, with Pancreas Cancer appearing as the primary indexed condition, and to 3 interventions - of which Secretin is the first listed.
NCT02000089 lists 9 locations in 7 states (New York, Pennsylvania, Connecticut).
Frequently Asked Questions
What is clinical trial NCT02000089 about?
NCT02000089 is a clinical study titled "The Cancer of the Pancreas Screening-5 CAPS5)Study". Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
What is the current status of trial NCT02000089?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 9,000 participants. The study started on 2014-01-06. Estimated completion is 2029-06.
What conditions does trial NCT02000089 study?
This clinical trial studies the following conditions: Pancreas Cancer, Lynch Syndrome, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier.
What interventions are being tested in trial NCT02000089?
The interventions under investigation include: Secretin (DRUG), MRI (DIAGNOSTIC_TEST), Tumor marker gene test with CA19-9 (OTHER).
Who is sponsoring clinical trial NCT02000089?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02000089 being conducted?
This trial has 9 study locations across Connecticut, Maryland, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02000089's enrollment target sits among peer trials
9,000 2nd of 54 the highest of 54 other Pancreas Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreas Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
RECRUITING · Phase 3
-
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05612347 · 8,946 participants · NA
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
- NCT06946355 · 9,119 participants · NA
Food-based Support for Hospitalized Children and Their Families
- NCT05336877 · 8,744 participants
Aveir VR Coverage With Evidence Development Post-Approval Study
- NCT06058234 · 8,680 participants
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI